Background and Aims Predictors of first-generation somatostatin receptor ligands (fgSRLs)
response in acromegaly have been studied for over 30 years, but they are still not …

'Pituitary tumours' is an umbrella term for various tumours originating from different regions
of the hypothalamic–pituitary system. The vast majority of pituitary tumours are pituitary …

Objective Provide insights into the defective POMC processing and invasive behavior in
silent pituitary corticotroph tumors. Design and methods Single-cell RNAseq was used to …

Predicting which acromegaly patients could benefit from somatostatin receptor ligands
(SRL) is a must for personalized medicine. Although many biomarkers linked to SRL …

Acromegaly results from growth hormone hypersecretion, predominantly caused by a
somatotroph pituitary neuroendocrine tumor (PitNET). Acromegaly-causing tumors are …

Introduction We previously described that a short version of the acute octreotide test (sAOT)
can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients …

Context The prompt control of acromegaly is a primary treatment aim for reducing related
disease morbidity and mortality. First-generation somatostatin receptor ligands (fg-SRLs) are …

Introduction Medical treatment of acromegaly is based in atrial and errorapproach. First-
generation somatostatin receptor ligands (fg-SRL) are prescribed as first-line medical …

Purpose Invasive non-functional pituitary adenomas (NFPAs) constitute 35% of NFPAs.
Despite a relatively large body of molecular investigations on the invasiveness of NFPA, the …

Acromegaly is caused by excess growth hormone (GH) produced by a pituitary tumor. First-
generation somatostatin receptor ligands (SRLs) are the first-line treatment. Several studies …